<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">

Champions Oncology Announces the Formation of Corellia AI, a Wholly Owned Biotech that Leverages Unique AI-Enabled Workflows for Novel Therapeutic Development

Apr 26, 2023 11:27:08 AM / by Champions Oncology

Hackensack, NJ - April 17, 2023 

Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled research organization that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic (PPMO) integration, announced the launch of its therapeutic discovery and development platform into a wholly owned subsidiary named Corellia AI (Corellia). Corellia launches out of Champions Oncology with a team of world class scientists advancing a robust pipeline of therapeutic programs and a unique discovery and development platform. The company will continue to leverage Champions' superior PDX Molecular Atlas and its living bank of PDX models as central tools in its proprietary target and therapeutic discovery platform.

Read More →

Champions Oncology Reports Quarterly Revenue of $12.8 Million

Mar 16, 2023 5:10:07 PM / by Champions Oncology

Hackensack, NJ - March 15, 2023 Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its third quarter of fiscal 2023, ended January 31, 2023.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $14.3 Million

Dec 14, 2022 12:38:59 PM / by Champions Oncology

Hackensack, NJ - December 13, 2022 Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its second quarter of fiscal 2023, ended October 31, 2022.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $13.7 Million

Sep 9, 2022 11:38:02 AM / by Champions Oncology

Hackensack, NJ - September 8, 2022 Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its first quarter of fiscal 2023, ended July 31, 2022.

Read More →

Champions Oncology Reports Quarterly Revenue of $12.9 Million

Jul 23, 2022 6:58:54 PM / by Champions Oncology

Hackensack, NJ - July 21, 2022 Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for the year and fourth fiscal quarter ended  April 30, 2022.

Read More →